spacer
home > epc > spring 2009 > paediatric protection
PUBLICATIONS
European Pharmaceutical Contractor

Paediatric Protection

Most medicines used in children have not been assessed or developed properly, and about 50 to 85 per cent of drugs are not licensed for use in children. Despite the lack of sufficient information about a drug, clinicians are still willing to prescribe products off-label, carefully considering the risk and benefit ratio. The administered dosages of many drugs that are being used in children are calculated based on extrapolations from the adults’ drug doses using the respective child’s weight or age. However, this can be dangerous and possibly lead to underdosing, overdosing or specific adverse events. Over the years, we have come to appreciate that there are indeed differences between children and adults with respect to general metabolism, renal clearance, anatomy, physiology and drug metabolism. These differences have highlighted the fact that children are not just smaller adults, but that they actually have their own peculiarities (1). In the US, where paediatric regulation has been in place longer than in Europe, it can be observed that under FDAMA, important dosing changes and safety information have been added to drug labels, providing more information on dosing regimens and important adverse events warnings. One such example is that of Fluoxetine (Prozac), which had a major label change so that it now warns clinicians prescribing it that they should monitor the height and weight of the paediatric patients and administer the drug appropriately. Another case is that of Gabapentin, which, after paediatric studies were carried out, demonstrated that higher doses were required to control seizures in patients of a younger age group, and a new set of adverse events were recognised (2).


Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer

Dr John Bolodeoku trained as a Chemical Pathologist and Metabolic Physician in the UK. His doctorate experience is in diagnostic molecular pathology in cancer, gained at the University of Oxford, where he was sponsored by a grant from Boehringer Mannheim. During his training in the clinics and laboratories, he has been a clinical investigator in Phase IIIb/IV studies for UpJohn (Lipids), Novartis (Lipids) and Roche (Obesity), and collaborated with R&D sytems (Diagnostics) in evaluating ELISA kit for adhesion molecules such as CD44. The pharmaceutical appointments he has held include Clinical Pharmacology Physician for a UK CRO (BIOS), Medical Adviser for Pfizer, UK and Medical Affairs Manager for Yamanouchi Europe. Currently he is Vice President, Medical Affairs and Health Economics for  Astellas Pharma, EMEA and Honorary Consultant Physician, North Hampshire Hospital, UK.

spacer
John Bolodeoku
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

Pharmaceutical Packaging and Labelling Summit in Zurich; ACG presentation

At next week’s Pharmaceutical Packaging and Labelling Summit in Zurich (18-19 June), Dr. Eugen Hertel from ACG will be speaking on: Challenges for Global Pharma companies to Implement Anti-Counterfeit Strategy for Russian Track & Trace Regulation. This presentation will include details around ‘the fight against counterfeit medicine - there have been and still are worldwide initiatives to make the supply chain and the safety of medicines secure. After large markets such as the USA and Europe passed their laws and regulations for the pharmaceutical manufacturing companies and established the IT infrastructure, Russia is now next on the move.
More info >>

White Papers

Maximize the ROI of Your Post-Approval Research

Bioclinica

Expenditures in post-approval (Phase IV) research are going up across the pharmaceutical, biotech and medical device industries. Given the resources you’ve committed to post-approval research, you may be wondering if you’re getting the greatest possible return on your investment. Discover how to harness the power of post-approval research to increase data collection, reduce resource burn, save money, and maximize your ROI!
More info >>

 
Industry Events

SAPHEX 2019

23-24 October 2019, GALLAGHER CONVENTION CENTRE, 10 RICHARDS DRIVE, HALFWAY HOUSE, MIDRAND, 1685, SOUTH AFRICA

SAPHEX 2019 will be held on the 23rd-24th October at the Gallagher Convention Centre, Johannesburg, South Africa.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement